QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.117051v1 321/2/583    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roos, N. Articles by Verrecchia, F. Search for Related Content PubMed PubMed Citation Articles by Roos, N. Articles by Verrecchia, F.

CELLULAR AND MOLECULAR

In Vitro Evidence for a Direct Antifibrotic Role of the Immunosuppressive Drug Mycophenolate Mofetil

Institut National de la Santé et de la Recherche Médicale U697, Paris, France (N.R., N.P., D.F., A.M., F.V.); and Service de Médecine Interne (D.F.) and Pharmacie (I.M.), Hôpital Saint-Louis, Paris, France

The immunosuppressive drug mycophenolate mofetil (MMF) is used to prevent organ rejection after transplantation and has shown some efficacy to prevent the fibrotic complications that occur during autoimmune diseases such as systemic sclerosis or during graft-versus-host disease (GVHD). We tested the hypothesis that MMF may exert direct effects on fibroblast extracellular matrix remodeling. Incubation of human lung fibroblast cultures with MMF led to dose- and time-dependent reduction in the synthesis and expression of type I collagen. Inhibition of COL1A1 and COL1A2 mRNA steady-state levels occurred at the level of transcription via repression of their promoters. In contrast, MMF significantly enhanced the expression and the synthesis of interstitial collagenase (matrix metalloproteinase-1). MMF was also found to diminish the capacity of fibroblast to contract mechanically unloaded collagen lattices and to reduce the synthesis of -smooth muscle actin, a marker of the contractile myofibroblast phenotype. In addition, MMF diminished the fibroblasts motility. In conclusion, we provide novel mechanism by which MMF alters fibroblast functions important for wound healing and implicated in the development of tissue fibrosis, e.g., collagen production, extracellular matrix contraction, and cell migration. Such properties may contribute to the beneficial therapeutic effects of MMF against fibrotic lesions developing in systemic sclerosis or during GVHD.

Address correspondence to: Dr. Franck Verrecchia, Institut National de la Santé et de la Recherche Médicale U697, Hôpital Saint-Louis, Pavillon Bazin, 1 Avenue Claude Vellefaux, 75010 Paris, France. E-mail: franck.verrecchia{at}stlouis.inserm.fr

This article has been cited by other articles:

				S. Adler, S. Lodermeyer, J. Gaa, and U. Heemann Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis Rheumatology, October 1, 2008; 47(10): 1535 - 1538. [Abstract] [Full Text] [PDF]

				L. A. Saketkoo and L. R. Espinoza Rheumatoid Arthritis Interstitial Lung Disease: Mycophenolate Mofetil as an Antifibrotic and Disease-Modifying Antirheumatic Drug Arch Intern Med, August 11, 2008; 168(15): 1718 - 1719. [Full Text] [PDF]

				R. Hanvesakul, C. Kubal, S. Jham, E. Sarkar, K. Eardley, D. Adu, and P. Cockwell Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients Nephrol. Dial. Transplant., July 12, 2008; (2008) gfn387v1. [Abstract] [Full Text] [PDF]